We are live on ! Find out more
IMUC.WS

ImmunoCellular Therapeutics Ltd.
IMUC.WS

Delisted

IMUC.WS was delisted on the 16th of October, 2018.

Back to rankings

4 hedge funds and large institutions have $55K invested in ImmunoCellular Therapeutics Ltd. in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $54K → $55K (+$1K)

0% more funds holding

Funds holding: 4 → 4 (0)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.3K
2
SM
Sabby Management
Florida
-$1.24K
3
UBS Group
UBS Group
Switzerland
-$62
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$37K – – –
SM
2
Sabby Management
Florida
$16K -$1.24K -27,401 -7%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2K -$2.3K -50,637 -54%
UBS Group
4
UBS Group
Switzerland
– -$62 -1,358 -48%

IMUC.WS Hedge Fund Activity: Q4 2017 in Review

4 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q4 2017, worth a combined $55K — up 1.9% from $54K a quarter earlier.

Fund positioning in IMUC.WS was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.

The largest seller was Susquehanna International Group, cutting an estimated $2.3K.

  • 4 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $55K of ImmunoCellular Therapeutics Ltd. stock for Q4 2017, up 1.9% quarter-over-quarter.
  • 0 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q4 2017 and 0 closed out.
  • The largest ImmunoCellular Therapeutics Ltd. seller in Q4 2017 was Susquehanna International Group, an estimated $2.3K sold.

Based on aggregated 13F filings for Q4 2017.